Drugs / Lysine
Lysine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | LysaKare | — | 2019-07-25 | europa.eu ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials · 1 missed | ||||||
| Phase 0 | NCT03440970 | Jan 2019 → Aug 2025 | heart failure | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT03446651 | Jul 2018 → Sep 2022 | heart failure | Yale University | Completed | Missed primary |
| Phase 11 trial | ||||||
| Phase 1 | NCT03478358 | Apr 2017 → Dec 2022 | neuroendocrine neoplasm | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03273712 Background | Sep 2017 → May 2020 | medulloblastoma, meningioma, neuroblastoma, neuroendocrine neoplasm | University of Iowa | Completed | No outcome recorded |
| Phase 2 | NCT03013387 Background | Jan 2017 → Oct 2018 | medulloblastoma, meningioma, neuroblastoma, neuroendocrine neoplasm | Sue O'Dorisio | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lysine | “Lysine and Arginine” NCT03013387 ↗ |
| Known as | Lisina | ChEMBL registry synonym — accepted as the source's own label CHEMBL8085 ↗ |
| Known as | Lysine Chloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03446651 ↗ |
| Modality | Other / unclassified | “This is a solution of amino acids” NCT03273712 ↗ |
| Route | Intravenous | “The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and amino acids (lysine and arginine).” NCT03478358 ↗ |